PTC Therapeutics | PTCT - Operating Expenses


PTC Therapeutics reported $246.3M in Operating Expenses for its fiscal quarter ending in December of 2025.





Operating Expenses Change Date
Acadia Pharmaceuticals USD 242.88M 10.68M Sep/2025
Alnylam Pharmaceuticals USD 965.32M 84.27M Dec/2025
Amgen USD 5.9B 773M Dec/2025
BioCryst Pharmaceuticals USD -387.89M 33.7M Sep/2025
Biogen USD 1.88B 81.4M Sep/2025
BioMarin Pharmaceutical USD 676.18M 131.65M Dec/2025
Cytokinetics USD 168.69M 9.58M Sep/2025
Daiichi Sankyo JPY 468.57B 15.34B Dec/2025
Enanta Pharmaceuticals USD 126.59M 346.51M Dec/2025
Esperion Therapeutics USD 67.66M 3.6M Sep/2024
Gilead Sciences USD 4.96B 707M Dec/2025
Incyte USD 1.12B 3.53B Dec/2025
Ionis Pharmaceuticals USD 316.9M 4.69M Sep/2025
Ironwood Pharmaceuticals USD 57.33M 8.63M Dec/2024
Karyopharm Therapeutics USD 61.82M 3.24M Dec/2024
Novartis USD 9.86B 115M Sep/2025
Pfizer USD 12.91B 79.89B Dec/2025
PTC Therapeutics USD 246.3M 38.78M Dec/2025
Puma Biotechnology USD 49.26M 3.2M Jun/2024
Roche Holding CHF 21.01B 10.84B Dec/2025
Sangamo BioSciences USD 33.87M 12.89M Jun/2024
Sarepta Therapeutics USD 462.23M 33.28M Sep/2025
TG Therapeutics USD 132.34M 26.04M Sep/2025
Ultragenyx Pharmaceutical USD 321M 9.82M Dec/2025
Vertex Pharmaceuticals USD 1.93B 89.1M Dec/2025
Xencor USD 68.52M 8.26M Sep/2025